Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 2Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 168Myelodysplastic Syndromes 160Leukemia 156Anemia 151Leukemia, Myeloid, Acute 144Neoplasms 124Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Leukemia, Myelomonocytic, Chronic 111Multiple Myeloma 90Myeloproliferative Disorders 89Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 76Hodgkin Disease 71Lymphoma 66Congenital Abnormalities 64Anemia, Refractory 64Venous Thromboembolism 63Thrombocytopenia 59Blast Crisis 57Leukemia, Myeloid, Chronic-Phase 56Leukemia, Myeloid, Accelerated Phase 52Lymphoma, Follicular 51Myelodysplastic-Myeloproliferative Diseases 48Anemia, Aplastic 46Primary Myelofibrosis 44Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 41Burkitt Lymphoma 41

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fractures, Spontaneous × Classical hematology × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡